| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | (How to Use This Table) company | is it aging ? | operating status | short summary (intended to be objective, usually from company website, edited for brevity) | clinical stage / pipeline | Tx or Dx | Aging Biotech .info company categories | hallmarks of aging | SENS damage categories | diseases / indications | clin. trials | modalities | regulatory category | team/principals (esp. scientific) | advisors (scientific) | contact info | geo(s) | public? | ticker Y! | market cap (M) | employees, Y! publics | employees LI | year founded | priv. fund. stage | notable investors | tot. raised ($M) | other relations | lead product(s) | publications | patents | date updated | add date if >Oct'19 | notes | ||
2 | 5 Alarm Bio | yes | operating | drugs to boost natural cell defenses against damaging chemicals that arise naturally & accumulate w/ age | pre-clinical | Tx | proteostasis | proteostasis | ex-cell aggregates? | small molecules | pharma | William Bains | Aubrey de Grey, Joao Pedro de Magalhaes | william@fivealarmbio.com | Cambridge, UK | no | 2016 | FAB001 | 2019-08-28 | ||||||||||||||||
3 | 712 North Inc | yes | operating | mitochondria modulators for age-related diseases | pre-clinical | Tx | mitochondria | mitochondria | mitochondria | AD, cancer, glaucoma, CVD, unspecificed orphan pediatric disease | pharma | Marcel Alavi | San Francisco | no | 2 | 2016 | QB3 | 2019-09-04 | |||||||||||||||||
4 | Aeovian (was Aeonian) | yes | operating | selective mTORC1 inhibition | pre-clinical | Tx | metabolism / mTOR | nutri-sense | small molecule | pharma | Stelios Tzannis, Curtis Scribner | Ian Massey, David Lowe, Dudley Lamming, Mustafa Sahin, Jacqueline French | form | San Francisco | no | 3 | 2012 | raised A | Apollo, venBio, Sofinnova | 37 | AE116 | paper | 2019-10-08 | ||||||||||||
5 | Age Labs | yes | operating | ML on methylation data mortality clock from longitudinal (45yrs) data, for improved clinical trials | pre-commercial | Dx | biomarkers / methylome clock | epigenetic | blood test | unreg test | Espen Riskedal, Arne Soraas, Karl Kalleberg | Oslo, Norway | no | 2 | 2017 | Norway | 2019-09-04 | ||||||||||||||||||
6 | AgeCurve Limited | yes | operating | DTC proteomics from saliva using mass spec & ML covering 7 of 9 hallmarks | commercial | Dx | biomarkers / proteome | saliva sample | unreg test | Attila Csordas | Aubrey de Grey, Daniel Reda, Kathryn Lilley | Cambridge, UK | no | 2 | 2015 | raising seed | LongevityTechFund | 2020-09-01 | |||||||||||||||||
7 | AgeX Ther. / Reverse Bio | yes | operating | allogeneic stem cells w/ tech for stable engraftment & low immunogenicity; tissue regeneration drugs | pre-clinical | Tx | stem cells, reprogramming | stem cells, epigenetic | cell loss | IHD, T2D, CHF, scarless healing | cell therapy, small molecules | pharma | Mike West, Aubrey de Grey | San Francisco | yes | AGE | $81 | 12 | 13 | 2017 | Juvenescence, Jim Mellon, John Mauldin, Kizoo | Juvenescence | VASC1, BAT1, iTR1547, Renelon | 2020-01-29 | AgeX has spun its iTR (reprogramming) work into a subsidiary called Reverse Bioengineering. | ||||||||||
8 | Alector | only brain | operating | modulate immune system to cure dementias w/ leads based on GWAS & guided by biomarkers | ph.2 trials | Tx, Dx | proteostasis | proteostasis | ex-cell aggregates | AD, FTD, neuroDs | 4 | biologics | pharma | Arnon Rosenthal, Robert Paul | Adam Boxer, Marco Colonna, Stephen Hauser, Michael Heneka, Lewis Lanier, Liqun Luo, Richard Scheller, Thomas Christian Südhof, Robert Vassar, Berislav Zlokovic | San Francisco | yes | ALEC | $1,375 | 101 | 104 | 2013 | Orbimed, Polaris, GV, Merck, MBC, AbbVie, Amgen | AbbVie | AL001, AL101, AL002, AL003 | many papers | 2019-09-18 | ||||||||
9 | Alkahest | yes | operating | leads from blood proteins that go up or down with age, eg young blood fractions | ph.2 trials | Tx | factors | cell comm | AD, PD, (wet) AMD, ESRD MCI | 11 | drugs, biologics, blood fractions | pharma | Karoly Nikolich, Steven Braithwaite | Tony Wyss-Coray, Jeffrey Cummings, Lennart Mucke, Thomas Rando, Eric Reiman, Lee Rubin, Elia Stupka, Saul Villeda | info@alkahest.com | San Francisco | acquired (by Grifols) | 71 | 2014 | acquired | Grifols, MJFox Found | 50 | Grifols | AKST4290, AKST/GRF6019/6021, AKST1210 | papers | 2020-09-10 | |||||||||
10 | Altoida | only brain | operating | augmented reality & AI mobile app 10min cognitive test, FDA cleared & covered by Medicare | commercial | Dx | biomarkers, proteostasis? | proteostasis? | ex-cell aggregates? | AD, other MCI | 1 | mobile app | reg Dx (SaMD) | Richard Fischer, Ioannis Tarnanas | Walter Greenleaf, Jon VanLeeuwen, Phil Polakoff | contact@altoida.com | Houston | no | 13 | 2016 | raised A | M Ventures, Fyrfly | 8.3 | NMI (Neuro Motor Index) | peer reviewed paper | 2019-07-22 | |||||||||
11 | Ambrosia | yes | operating, see notes | infusions of young blood from donors aged 16-25 for 30+ year-olds for $5500+ | clinical trial, phase n/a | Tx | factors | cell comm | 1 | blood transfusion | ? | Jesse Karmazin | form | San Francisco | no | 1 | 2016 | 2020-01-23 | Back to operating? ambrosiaplasma.com & linkedin.com/in/jessekarmazin down in Aug'19 but back in Jan'20. See also: bloomberg.com/news/articles/2019-02-25/the-bloody-tale-of-ambrosia-the-startup-that-wants-to-slow-aging, webmd.com/healthy-aging/news/20190220/young-blood-clinics-shut-down-after-fda-action, & longevity.technology/young-blood-back-on-the-menu/ | ||||||||||||||||
12 | Amprion | only brain | operating | amplification of misfolded proteins for sensitive detection in CSF & blood, for αS (1st), Aβ, tau | pre-clinical, breakthrough | Dx | proteostasis | proteostasis | ex-cell aggregates | PD, AD | CSF | reg test? device? | Russ Lebovitz, Claudio Soto, Luis Concha | Info@AmprionMe.com | San Diego, San Francisco | no | 8 | 2007 | 2019-09-30 | Breakthrough device designation from FDA in May 2019 for alpha-Synuclein. Not to be confused with the Germany electrical grid company of the same name. | |||||||||||||||
13 | Animal Biosciences | yes | operating | healthy longevity for pets (primarily dogs, cats, horses) | pre-vet-clinical | Tx | small molecules, supplemens | veterinary | Doug Korn, Nick Sinclair | form | Boston | no | 6 | Life Bio | Life Bio | 2019-10-08 | |||||||||||||||||||
14 | Antoxis | yes | IP only? | platform for mito drugs, 1st as co-treatments for regen. med. & cancer therapies, & for neuroDs | pre-clinical | Tx | mitochondria | mitochondria | mitochondria | neuroDs, cancer, regenerative med. | drugs | pharma | only board? | Donald McPhail | info@antoxis.com | Aberdeen, Scotland | no | 0 | 2005 | Grampian, Genomia, TriCap | £ 2M | Proxison, Oncamex | 2018 paper | 4 patents | 2020-01-03 | 2020-01-03 | Company has a 2nd LinkedIn page: https://www.linkedin.com/company/antoxis-limited/ Also see news piece from 2012: https://www.sciencescotland.org/feature.php?id=182 | ||||||||
15 | Athersys Inc | yes | operating | allogeneic stem cells for neuro, inflammatory, immune, & CV diseases | ph.3 trials | Tx | stem cells | stem cells | cell loss | neuroDs, CVD, others | 9 | cell therapy | pharma | Gil Van Bokkelen, John Harrington, William (BJ) Lehmann, Robert (Willie) Mays, Anthony Ting | info@athersys.com | Cleveland, OH | yes | ATHX | $431 | 75 | 89 | 1995 | MultiStem | 2019-07-11 | |||||||||||
16 | Atropos Therapeutics | yes | operating | drug platform for modulators of entering senescence, for aging (suppress) & cancer (stimulate) | pre-clinical | Tx | senescence | senescence | senescence | cancer, progeroidDs, undecided agingDs | small molecules? | pharma | Andrew Koff, Nathanie Trisnadi | Jan Vijg, John Sedivy, William Tap, John Petrini, Oliver Stauch, Teresa Calarco | info@atroposthera.com | San Francisco | no | 5 | 2018 | QB3, Atomwise | some relevant papers | 2020-02-04 | Sept'19 announced partnership with Atomwise to do AI for drug discovery for cancer via senescence modulation. | ||||||||||||
17 | Aurora Bio | yes | operating | diagnosis & therapy for systemic non-CSF amyloid diseases (AL, ATTR, LECT2) | ph.1 trials | Dx, Tx | proteostasis | proteostasis | ex-cell aggregates | systemic amyloidosis | 1 | peptides | pharma, reg Dx | Spencer Guthrie, Jonathan Wall, Nancy Miller-Rich | Jeff Kelly, Morie Gertz, Matthew Maurer | form | San Francisco | no | ? (no page & too many name conflicts) | 2019 | QB3 | AUR01 / P5+14 | 2020-01-04 | 2020-01-04 | Not to be confused with several other companies called Aurora Bio: Sydney based medical device maker Aurora BioScience, cancer company Aurora BioPharma, drug discovery system company Aurora Biosciences (acquired by Vertex in 2001) | ||||||||||
18 | Beiwe Health | yes | operating | non-rapalog mTORC1 inhibitors using new site on mTOR, for aging & cancer (esp. glioblastoma) | pre-clinical | Tx | metabolism / mTOR | nutri-sense | cancer | pharma | Sonia Allen, Alexey Tomilov, Gino Cortopassi | form | Sacramento, CA | no | 1 | 2018 | 2020-03-02 | 2020-03-02 | |||||||||||||||||
19 | BHB Therapeutics | yes | operating | beta-hydroxybutyrate (BHB) | Tx | Eric Verdin? John Newman? | no | raised seed | Juvenescence | 3 | Juvenescence | 2020-03-02 | 2020-03-02 | ||||||||||||||||||||||
20 | BioAge Labs | yes | operating | human 20+yr biobanks + multiomics + AI drug platform; leads: HIF signaling, PGD2 DP1 for immune aging | pre-clinical ph.2 ready | Tx | biomarkers, immune, stem cells? or factors? | cell comm | muscleDs, immuneDs, COVID-19 | drugs | pharma | Kristen Fortney, Eric Morgen, Paul Rubin, Klaus Klumpp, Robert Hughes, Justin Rebo | George Hartman, Elad Gil, Joe Betts-Lacroix, Eric Verdin, Peter Dilaura, ... | info@bioagelabs.com | San Francisco | no | 30 | 2015 | closed B | Felicis, Andreessen Horowitz, Khosla, AME Cloud, Pear, Redpoint, Caffeinated Captial, Elad Gil | 34 | BGE117, BGE-175 | paper (not core) | 2020-08-30 | |||||||||||
21 | BioChange ltd | ||||||||||||||||||||||||||||||||||
22 | Biophytis | yes | operating | drug discovery platform for aging based on plant secondary metabolites | ph.2 trials | Tx | sarcopenia, AMD, MD | 2 | small molecules | pharma | Stanislas Veillet, Rene Lafont, Samuel Agus, Pierre Dilda, Waly Dioh | Jean Mariani, Roger Fielding, Thomas Voit, Jose-Alain Sahel, Ivana Kim | form | Paris | yes | ALBPS.PA | $145 | 30 | 26 | 2006 | Sarconeos (BIO101), Macuneos (BIO201) | several papers & posters | 2019-07-11 | ||||||||||||
23 | Bioquark | yes | operating | biologics for regeneration, repair, degenerative diseases w/ leads from regenerative animals | ph.1 trials | Tx | cancer, kidneyDs, neuroDs, brain death | 1 | biologics, cell therapy | pharma | Ira Pastor, Sergei Paylian | Calixto Machado, Melisa Cooper, Alejandro Mesples, Nikolai Skiba | form | Philadelphia, Tampa | no | 10 | 2007 | BQ-A | two (see bottom) | 2019-07-28 | |||||||||||||||
24 | BioViva | yes | operating | platform for health tests & treatments (via partners) w/ focus on gene & cell therapies, also counseling | commercial | Elizabeth Parrish, Jason Williams, Anca Selariu, Mitch Fernandez, David Kekich | George Church, Bill Zheng, Anders Sandberg, John Schloendorn, Ali Fallah, Aubrey de Grey, Matthew Scholz, Hernando Ramirez Llinas | form | Seattle | no | 3 | 2015 | Integrated Health Systems | 2019-08-13 | CEO Parrish underwent out-of-USA gene therapy to extend her telomeres w/ hTERT and for myostatin inhibition then claimed positive results, back when company focus was more directly telomere extension therapy. See also https://en.wikipedia.org/wiki/BioViva | ||||||||||||||||||||
25 | Blue Rock Therapeutics | yes | operating | universal pluripotent stem cell lines for allogeneic cell therapies for neuro-/cardio-/immunology | pre-clinical | Tx | stem cells | stem cells | cell loss | PD, neuroDs, HF | cell therapy, gene therapy | pharma | Emile Nuwaysir, Robert Deans, Joachim Fruebis | Gordon Keller, Michael Laflamme, Lorenz Studer, Viviane Tabar, Bruce Blazar | form | Boston, New York, Toronto | acquired (by Bayer) | 124 | 2016 | acquired | Bayer | 225 | Bayer | 2020-01-05 | 2020-01-05 | ||||||||||
26 | BYOMass Therapeutics | yes | operating | control of metabolism for aging / age-related diseases | pre-clinical | Tx | metabolism | nutri-sense | pharma | Margaret Jackson | chris@juvenescence.ltd | Massachusetts | no | 1 | 2017 | raised seed | Juvenescence | 6.5 | Juvenescence | 2020-04-29 | |||||||||||||||
27 | Calico | yes | operating | broad mission to improve health and longevity using technology to advance biological science | Tx | pharma | Arthur Levinson, David Botstein, Cynthia Kenyon, Daniel Gottschling | press@calicolabs.com | San Francisco | no | 180 | 2013 | 2 rounds | Google, Abbvie | 2500 | Google, AbbVie | several | 2019-08-19 | Initially funded/created within Google/Alphabet. | ||||||||||||||||
28 | Celevity / Cellular Longevity | yes | operating | drug(s) to treat aging in dogs | pre-vet-clinical | Tx | drugs | veterinary | Celine Halioua | no | 0 | 2019 | funded | Longevity Fund, Collaborative Fund, Bedrock, Village | Longevity Fund | 2019-12-19 | 2019-12-19 | ||||||||||||||||||
29 | CellAge | yes | operating? | develop new, more accurate senescent cell measurement based on synthetic promoters | research, pre-commercial | Dx | senescence | senescence | senescence | unreg test | Mantas Matjusaitis, Azuolas Ciukas | Alexandra Stolzing, Juan Carlos Acosta | INFO@CELLAGE.ORG | Glasgow, Scotland | no | 2 | 2016 | raised seed | Kizoo | Circularis | 2019-08-02 | Website is .org. Seed raise was 2017 & involved crowdfunding. No mention of total raised. Still only 2 employees? Is this a for-profit company? | |||||||||||||
30 | Celularity | yes | operating | allogeneic cell therapies from postpartum human placentas, for cancer & functional regeneration | ph.2 trials | Tx | stem cells | stem cells | cell loss | cancer (solid & blood), others | cell therapy | pharma | Robert Hariri, Xiaokui Zhang, Nassir Habboubi | media@celularity.com | New York | no | 155 | 2016 | Celgene, Bill Maris, Tony Robbins, Human Longevity | 290 | CYNK-001 | thousands | 2019-08-19 | Also run income generating programs to bank placental stem cells and to treat burns & wounds, with projected $40M revenue. | |||||||||||
31 | Centaura | yes | starting? | reverse aging by affecting core biological mechanisms at the cellular level using multi-omics data | Tx | Brian Kennedy, Joao Pedro De Magalhaes, Vadim Gladyshev, Vera Gorbunova, Andrei Seluanov, Jerry Shay | Info@centaura.com | Zurich | no | 7 | 2018 | 2020-09-01 | 2020-09-01 | ||||||||||||||||||||||
32 | Centers for Age Control | yes | operating | sells AgeMeter multimodal test of biological age (successor to H-SCAN test) | commercial | Dx | biomarkers | multimodal test | unreg test | Elliot Small | info@agemeter.com | Las Vegas | no | 1 | 2005 | crowdfunded | AgeMeter | 2019-08-22 | |||||||||||||||||
33 | Cerevance | only brain | operating | drug discovery platform by analyzing brain cell transcriptome diffs by age, cell type, region, & disease | ph.2 trials | Tx | PD, AD, ALS, neuroDs | 5 | small molecules, mAbs | pharma | Brad Margus, Mark Carlton, David Margolin, Lee Dawson, Roland Burli | Nathaniel Heintz, William Ray, Robert Malenka, James Summers, Jeremy Nathans, Rudolph Tanzi | info@cerevance.com | Boston | no | 35 | 2016 | raised A | Takeda Pharm, Dementia Discovery Fund, Lightstone | 26.5 | CVN424 | paper | 2020-03-04 | ||||||||||||
34 | ChromaDex | yes | operating | nutraceuticals for aging, esp. flagship product Niagen w/ nicotinamide riboside (NR), an NAD+ precursor | commercial, ph.3 trials | Tx | NAD+ | cancer, MCI, HF, mitoDs, more... | 25 | nutraceuticals | supplement | Rob Fried, Frank Jaksch Jr., Matthew Roberts | Roger Kornberg, John Walker, Rudolph Tanzi, Charles Brenner, Rob Beudeker, Bruce German | multiple emails & form | Los Angeles | yes | CDXC | $589 | 100 | 95 | 1999 | Niagen | many | 2019-08-05 | 13 clinical trials mentioning Chromadex, but fewer sponsored by Chromadex and 23 trials using Niagen (some just not mentioning Chromadex by name). | ||||||||||
35 | Chronomics | yes | operating | DTC saliva methylation clock, plus software to improve health | commercial | Dx | biomarkers / methylome clock | saliva sample | unreg test | Tom Stubbs, Robin Thompson, Daniel Herranz | Janet Thornton, Paolo Vineis | info@chronomics.co.uk | London | no | 12 | 2017 | raised seed | SOSV, Anthemis, RebelBio | 1.3 | EpiHealth | 2019-10-18 | ||||||||||||||
36 | Cleara Biotech | yes | operating | senolytics, initially based on FOXO4-p53 interfering peptide | pre-clinical | Tx | senescence | senescence | senescence | peptide or small molecules? | pharma | Peter De Keizer, Tobias Madl, Marco Demaria | Boudewijn Burgering | form | Netherlands | no | 5 | 2018 | raised seed | Apollo | several, esp. Cell 2017 | 2019-07-11 | |||||||||||||
37 | CohBar Inc | yes | operating | find mtDNA peptides (eg that decrease w/ age) & optimized analogs to treat metabolic dysfunction | ph.1 trials | Tx | mitochondria | mitochondria | mitochondria | NASH, obesity, T2D, cancer, other ageDs | 1 | peptides | pharma | Steven Engle, Kenneth Cundy, Nir Barzilai, ... | Amir Lerman, David Sinclair, Ronald Kahn, James Livingston, Frank Calzone | info@cohbar.com | San Francisco | yes | CWBR | $96 | 11 | 14 | 2007 | CB4211 | papers & posters | 2019-10-16 | |||||||||
38 | Continuum Biosciences | yes | operating | drugs to improve mitochondria health & metabolism (eg to increase metabolism) | pre-clinical | Tx | mitochondria | mitochondria, nutri-sense | mitochondria | NASH, obesity, diabetes | drugs | pharma | Simon Tucker, Webster Santos, Kyle Hoehn | John Amatruda, David Sinclair | form | Blacksburg, VA | no | 2 | 2017 | raised seed | Life Bio | 0.5 | Life Bio | 2019-10-17 | Not to be confused with Continuum Biosciences Consulting: https://www.continuumbiosciences.com/ | ||||||||||
39 | Covalent Bioscience | yes | operating | platform for catalytic antibodies (w/ advantages over mAbs) 1st for ATTR & Aβ, electrophilic vaccines | pre-clinical | Tx, preventative | proteostasis, targeted elimination | proteostasis | ex-cell aggregates | CVD, AD, HIV | pharma | Richard Massey, Sudhir Paul, Stephanie Planque | Robert Friedland, Joel Buxbaum, Miguel Escobar, Carl Hanson, Seth Pincus | form | Houston, New York | no | 3 | 2011 | several peer reviewed | 2019-08-03 | |||||||||||||||
40 | Cytegen | yes | operating | exercise mimetic biologics to treat mitochondria dysfunction | pre-clinical | Tx | mitochondria, metabolism | mitochondria | mitochondria | AD, Parkinson's | biologics | pharma | George Ugras, Blake Hill | San Francisco | no | 2 | 2015 | raised unspecified | Breakout | 1 | 2019-12-19 | ||||||||||||||
41 | Daphnia Labs | yes | operating | drug discovery platform via in-vivo phenotypic screens of daphnia water fleas w/ video & ML for anti-aging | pre-clinical | Tx | lifespan screens | pharma | Sarah Constantin | info@daphnia-labs.com | San Francisco | no | 2 | 2019 | 2019-08-02 | ||||||||||||||||||||
42 | Deciduous Therapeutics | yes | operating | activate endogenous immune cells to clear senescent cells | pre-clinical | Tx | senescence | senescence | senescence | pharma | Robin Mansukhani | San Francisco | no | 5 | 2018 | raised seed | JLABS, MBC, Longevity Fund, CRV | 5.9 | QB3, Age1 | 2020-02-20 | |||||||||||||||
43 | Denali Therapeutics | only brain | operating | drug discovery for neurodegeneration, optimized for brain delivery, guided by genetics & biomarkers | ph.1 trials | Tx | PD, ALS, AD, FTD, MS, neuroDs | 5 | small molecules, biologics | pharma | Ryan Watts, Carole Ho, Zach Sweeney | Scott Biller, David Holtzman, Eric Reiman, Kevan Shokat, Henrik Zetterberg, Huda Zoghbi, Marc Tessier-Lavigne | form | San Francisco | yes | DNLI | $7,753 | 230 | 237 | 2015 | DNL201, DNL151, DNL747 | 2019-08-22 | |||||||||||||
44 | Dorian Therapeutics | yes | operating | block cellular senescence | pre-clinical | Tx | senescence | senescence | senescence | pharma | Maddalena Adorno, Benedetta di Robilant | form | San Francisco | no | 4 | 2018 | Longevity Fund, YC, Blumberg | MBC | 2019-08-06 | ||||||||||||||||
45 | Elevian | yes | operating | regulate GDF11 & other circulating factors to restore regenerative capacity | pre-clinical | Tx | factors | cell comm | CVD, T2D, AD, sarcopenia | pharma | Mark Allen, Tony Sandrassagra, Manisha Sinha, Orit Foord, Vongting Wang | Brock Reeve, Luis Alvarez, Scott Dylla, James Larrick | info@elevian.com | Boston | no | 12 | 2017 | raised seed | Kizoo, Thynk, Longevity Fund, Bold | 5.5 | several | 2019-08-22 | |||||||||||||
46 | Elysium Health | yes | operating | supplement called Basis: NR + pterostilbene for boosting NAD+; plus DTC epigenetic clock | commercial, ph.1 trials | Tx, Dx | NAD+, biomarkers / methylome clock | epigenetic | 7 | nutraceuticals, saliva sample | supplement, unreg test | Eric Marcotulli, Leonard Guarente, Mark Morris, Morgan Levine | 25+ inc. George Church, Ana Maria Cuervo, Vera Gorbunova, Jim Kirkland | care@elysiumhealth.com | New York | no | 55 | 2014 | raised B | SV Bank, General Catalyst | 71 | Basis, Index | paper | 2020-01-06 | To launch epigenetic age clock in Jan 2020 based on work by new head of bioinformatics Morgan Levine. | ||||||||||
47 | Enclear Therapies | only brain | operating | devices to access & filter toxic proteins from CSF, 1st for ALS | pre-clinical | Tx | proteostasis | proteostasis | ex-cell aggregates | ALS, neuroDs | CSF access | device | Anthony DePasqua, Kevin Kalish, Kasper Roet, William Gormley | Kevin Eggan, Clifford Woolf, Manuel Navia, Bernhardt Trout | form | Boston | no | 9 | 2018 | raised A | 20/20 HealthCare, Thiel Capital, Amgen Ventures, Bioverge, Sanford Biosciences, Presight Capital | 12 | LabCentral | 2020-02-20 | Mostly a therapeutic company, but various company summaries also mention monitoring of CSF. | ||||||||||
48 | Epimorphy LLC | yes | operating | DTC Horvath methylation clock | commercial | Dx | biomarkers / methylome clock | epigenetic | blood test, urine test | unreg test | Larry Jia | info@myDNAge.com | Los Angeles | no | 0 | 2017 | Zymo Research | myDNAge | 2019-08-02 | ||||||||||||||||
49 | Eterly | yes | operating | AI based anti-aging health & fitness monitoring and recs app w/ blockchain coins for incentives | app launched | recs | software | unreg app | Andrew Ahachinsky | form | Vancouver, BC | no | 10 | 2016 | raised seed | Deep Knowledge Ventures | Longevity Token? | 2019-08-22 | What is the relationship to Longevity Token (LTY) / Longevity United, whose website mentions Eterly as its front-facing app and some team members overlap based on LinkedIn, but CEOs are different, LTY's website doesn't seem to have updates since early 2018, and Eterly website doesn't mention Longevity Token. Are they distinct legal organizations? | ||||||||||||||||
50 | Eternans | yes | operating | senolytics, peptide (see patent) | pre-clinical | senescence | senescence | senescence | pharma | Yavuz A. | form | UK | no | 3 | 2017 | patent | 2019-08-22 | ||||||||||||||||||
51 | Everon Biosciences | yes | defunct? | small molecules & biologics platform based on proprietary aging biomarkers including a frailty index | pre-clinical | Tx | Alexander Polinsky, Andrei Gudkov, Olga Chernova | info@everonbio.com | Buffalo, NY | no | 6 | 2010 | several | 2 | 2020-08-30 | News & publications end mid-2017. | |||||||||||||||||||
52 | Fauna Bio | maybe | operating | comparative animal genomics & multi-omics for drug discovery to improve human health | pre-clinical | Tx | form | San Francisco | no | 5 | 2018 | raised seed | Longevity Fund, True Ventures (lead) | 4.1 | Age1 | 2019-07-15 | Appears more committed to idea of using insights f/ non-model non-human organisms for human health broadly, not specifically for aging. In favor of categorizing as aging: Hibernation is a focus & relevant for age-related diseases. Aging is mentioned as a (distant) future area. Investment by Longevity Fund. Conclusion: Include but re-evaluate after seeing what indications, targets, pathways they go after initially. | ||||||||||||||||||
53 | Fountain Therapeutics | yes | operating | unbiased screening platform for new aging targets using AI, vision, & cellular model of aging hallmarks | pre-clinical | Tx | info@fountaintx.com | San Francisco | no | 4 | 2018 | Bold | 5 | QB3 | 2019-07-24 | ||||||||||||||||||||
54 | FoxBio / Antoxerene | yes | operating | drug platform using protein manufacturing tech, senolytics targeting p53 pathways (eg p53/FOXO4) | pre-clinical | Tx | senescence | senescence | senescence | small molecules | pharma | Kelsey Moody, Adam Blanden, Cees Wortel | info@ichortherapeutics.com | Syracuse, NY | no | 5 | 2016 | raised seed | Juvenescence, Kizoo | 11.5 | Ichor, Juvenescence | 2019-08-09 | Ichor spun out Antoxerene. Antoxerene & Juvenescence created FoxBio as a 50-50 joint venture. Considering them (A & FB) as one here for now since FB has no website nor LIn employees. | ||||||||||||
55 | FOXO Bioscience (was Life Epigenetics) | yes | operating | B2B epigenetic tests as a service (for pharma & nutraceutical clients, research, insurance) | commercial | Dx | biomarkers / methylome clock | life insurance | saliva sample | unreg test | Jon Sabes, Brian Chen, Randy Olson | Michael Curran, Morgan Levine, Raymond McCuley, Andreas Muller | info@lifeegx.com | Minneapolis | no | 19 | 2016 | subsidiary of GWG Holdings (a public company) | GWG Holdings | 2019-07-30 | [Company name updated 4/28/2020, but rest of row needs update, including rest of this cell.] Sister company YouSurance (also a subsidiary of GWG) in beta beginning to sell DTC life insurance (using Life Epigenetics service?) | ||||||||||||||
56 | GEn1E Lifesciences | yes | operating | drug discovery platform for inflammatory & aging diseases; lead is p38α kinase inhibitor | pre-clinical | Tx | acute lung injury, agingD? | pharma | Ritu Lal, Clint Webb, Wendy Luo | David Young, Alan Levy, Robert Booth, Leonard Hayflick | Info (@) GEn1Elifesci.com | San Francisco | no | 3 | 2018 | 2019-07-30 | Some profiles on 3rd party sites (older material?) omit mention of aging, instead saying a pipeline for rare diseases. No explanation p38 kinase inhibition's larger role in aging. Giving benefit of doubt for now for putting aging front and center and pledging age-related disease indications coming. | ||||||||||||||||||
57 | GenFlow Biosciences | yes | operating | gene therapies for aging in dogs & humans, especially relating to SIRT6 | pre-clinical | Tx | DNA | DNA | gene therapy | pharma | Eric Leire, Tongtis Tongyai | Eric Verdin, Matthew Hirschey, Vera Gorbunova, Aubrey de Grey, Manlio Vinciguerra | eric@genflowbio.com | Belgium | no | 2 | 2020 | SIRT6 related | 2020-10-01 | 2020-10-01 | |||||||||||||||
58 | Genome Protection | yes | operating | entolimod & other drugs for anti-aging & cancer, esp. by protecting genome, esp. against transposons | ph.2 trials | Tx | DNA / transposons | DNA | cancer | various cancers | 3 | small molecules | pharma | Andrei Gudkov, Yakov Kogan, Katerina Andrianova | info@genomeprotection.com | Buffalo, NY | no | 3 | 2018 | seed | Norma Investments | 10.5 | Everon, Cleveland Biolabs | entolimod (drug) | several inc. peer-reviewed | 2019-07-17 | also started with a portfolio of other anti-aging and anti-cancer drugs from parent Everon Biosciences | ||||||||
59 | GenSight Biologics | yes | operating | allotopic expression w/ targeting to deliver mRNA to mitochondria, for retinal & neuro mito diseases | ph.3 trials | Tx | mitochondria | mitochondria | mitochondria | NA eyeDs, AMD | 8 | viral gene therapy | pharma | Bernard Gilly, Magali Taiel, Catherine Cancian | Botond Roska, Jose-Alain Sahel, Jean Bennett, Ernst Bamberg, Connie Cepko, Serge Picaud, Luk Vandeberghe | form | Paris, New York | yes | SIGHT.PA | $344 | 28 | 39 | 2012 | 2020-01-06 | allotopic expression of mtDNA w/ targeting to deliver the mRNA to mitochondria could rescue mito aging; also in pre-clinical development for age-related dementias | ||||||||||
60 | Geras Bio | no website yet? mentioned in https://www.nature.com/articles/s41587-020-00750-1/tables/1 | |||||||||||||||||||||||||||||||||
61 | Gero | yes | operating | physics based data/AI biomarkers for licensing & therapy development | commercial, pre-clinical | Dx, TX | biomarkers | life insurance, ? | unreg test | Peter Fedichev, Maxim Kholin | info@gero.ai | Moscow, Singapore | no | 35 | 2015 | several, inc. peer reviewed | 2020-01-15 | ||||||||||||||||||
62 | Gerostate Alpha | yes | operating | pharmaceutical scerening platform to treat aging | pre-clinical | Tx | lifespan screens | pharma | Simon Melov, Gordon Lithgow, Mark Lucanic | SMELOV@GEROSTATEALPHA.COM | San Francisco | no | 5 | 2018 | YC, CRCM | 0.15 | 2019-09-12 | ||||||||||||||||||
63 | Gordian Biotechnology | yes | operating | unbiased, high-throughput, in-vivo screening platform for aging w/ gene therapy & single-cell RNAseq | pre-clinical | Tx | gene therapy | pharma | Francisco LePort, Martin Borch Jensen, Daniel Fuentes, Chris Towne | Tom Rando, Randy Platt, David Schaffer, Laura Deming, Edward Lanphier, Thomas Ebeling | info@gordian.bio | San Francisco | no | 5 | 2018 | Longevity Fund, NJF | QB3, Age1 | 2019-08-06 | |||||||||||||||||
64 | Guided Clarity | yes | operating | mitochondria-targeted therapies: trigger apoptosis in cancer, increase mitophagy for aging | pre-commercial | Tx | mitochondria | mitochondria | mitochondria | cancer, ageDs, neuroDs | Helen Chen, Olof Mollstedt | form | San Francisco | no | 2 | 2018 | SOSV/IndieBio | 2019-11-07 | |||||||||||||||||
65 | Hanako Biotech | yes | operating | screening platfom for oligonucleotide senolytics with high selectivity & senolytic activity | pre-clinical | Tx | senescence | senescence | senescence | oligonucleotides | pharma | Yuri Shoshan, Noam Pilpel, Amir Bar-Shai, Yossi Ovadya, Dina Raichlin | Ido Bachelet | info@hanako.bio | Israel | no | 1 | 2019 | 2019-11-13 | 2019-11-13 | |||||||||||||||
66 | Human Rejuvenation Biotechnologies | yes | defunct | clearance of 7-ketocholesterol (a type of lipofuscin) for atherosclerosis | pre-clinical | Tx | atherosclerosis | pharma | contact@human.bio | Phoenix, AZ | no | 0 | 2014 | Jason Hope | 2020-08-30 | Defunct: The handful of employeees on LinkedIn say their employment here ended. William Adams' (linked in this cell) says "closure of company". | |||||||||||||||||||
67 | Humanity Inc | yes | operating | aging-focused health/wellness platform using biomarkers & self-experimentation | pre-commercial | recs | software | unreg app | Michael Geer, Peter Ward | info@humanity.email | UK | no | 3 | 2019 | 2020-02-07 | ||||||||||||||||||||
68 | Ichor Ttherapeutics | yes | operating | biopharma that spins off subsidiaries inc. senolytics, enzymes for lipofuscin, a CRO, & oral mAb mimetics | pre-clinical | Tx | AMD, other undisclosed | small molecules, biologics | pharma | Kelsey Moody, Aaron Wolfe, Cornelis Wortel | info@ichortherapeutics.com | Syracuse, NY | no | 37 | 2013 | raised seed | Kizoo | 4.5 | Antoxerene, FoxBio, LysoClear, Auctus Biologics | several | 2019-08-24 | LysoClear itself doesn't qualify for this list due narrow 1-body-part (eye) & 1-disease focus, but the platform approach it came from does & lives in Ichor. Auctus could eventually qualify itself w/ similarities to Longevity Biotech, but too little info currently available publicly on indications it will target. | |||||||||||||
69 | InSilico Med. / Generait | yes | operating | Insilico: AI for drug discovery, biomarkers, & aging. Generait (formerly Juvenescence AI): JV for aging. | biomarkers | Alex Zhavoronkov, Marine Bozdaganyan, Ivan Ozerov, Jimmy Yen-Chu Lin, Polina Mamoshina | Charles Cantor, Michael Levitt, Bud Mishra, Donald Small, Yuri Nikolsky, Kristen Fortney, Alexey Moskalev, Ulrich Muehlner | zhu@insilicomedicine.com | Hong Kong, Moscow | no | 53 | 2014 | raised B | Qiming, Wuxi AppTec, Deep Knowledge Ventures, Juvenescence, Bold, Jim Mellon | 51.3 | Juvenescence | sevenal | 2019-09-10 | Mostly AI for drug discovery (like many others not focused on aging) but also consistently focused on aging, publishing on aging, launching aging-focused sites, creating aging-related partnerships, etc. Recent post on Medium suggests shifting focus away from aging. If that happens, Insilico will drop off this list though perhaps Generait might stay if a proper 1st-class company in the sense of others here by then. | ||||||||||||||||
70 | Integrated Health Systems | yes | operating | gives patients access to gene & cell therapies for anti-aging esp. telomeres & myostatin, BioViva partner | commercial | Tx | telomeres | telomeres | AD, cancer, kidneyDs | viral gene therapy | medical tourism | a team of doctors | info@integrated-health-systems.com | British Virgin Islands | no | 1 | BioViva | 2019-08-14 | Ex-USA travel not mentioned explicitly but apply-for-study link leads to https://mailchi.mp/bioviva-science.com/alzheimers/ which mentions travel to Mexico. Not to be confused with the other Integrated Health System (same exact name) at https://ihs911.com/ which does IT for senior living and related care facilities. | ||||||||||||||||
71 | Intervene Immune | yes | operating | reverse thymus involution & (immune) aging w/ HGH+DHEA+more; provide thru collaborating drs. | commercial, pre-clinical | Tx | immune | cell loss | Greg Fahy, Bobby Brooke | info@interveneimmune.com | Los Angeles | no | 2 | 2011 | Aging Cell, 2019 | patent | 2019-09-12 | TRIIM trial results published in 2019 showed Horvath clock reversal of 2.5yrs over 1yr of study. | |||||||||||||||||
72 | iuve bio | yes | operating | DTC biomarkers of systemic chronic inflammation based on Stanford 1000 immunomes project & AI | commercial | Dx | biomarkers | blood test | unreg test | Wolfgang Daum, Zuzana Krejciova-Rajaniemi | Mark Davis, David Furman, Joseph Wu | info@iuvebio.com | San Francisco | no | 2 | 2018 | Age1 | iAge | 2019-08-02 | ||||||||||||||||
73 | Juvena Therapeutics | yes | operating | discovery platform for proteins promoting tissue regeneration, using proteomics, vision, ML | pre-clinical | Tx | stem cells, factors | stem cells, cell comm | cell loss | biologics | pharma | Hanadie Yousef, Jeremy O'Connell | Mike Nohaile, David Schaffer, Joe Wu, Peter Jackson, Irina Conboy | form | San Francisco | no | 10 | 2017 | raised seed | Felicis, Compound, Front Seat, Barney Pell | 4.3 | Youssef's patents | 2019-09-13 | ||||||||||||
74 | Juvenescence | yes | operating | biopharma umbrella company that creates/invests-in other companies for aging therapeutics | see portfolio | Tx | umbrella | Greg Bailey, Declan Doogan, Colin Watts, Alexander Pickett, Margaret Jackson, Nafees Malik | Annalisa Jenkins, Steve Felstead, Howard Federoff, Sef Kurstjens, Charlie Roberts, Jeff Sprouse | form | London | no | 10 | 2016 | raised B | Foresite, Grok, IPGL, Jim Mellon | 165 | several portfolio companies | 2019-08-26 | ||||||||||||||||
75 | Life Biosciences | yes | operating | biopharma umbrella company that creates/invests-in other companies for aging therapeutics | see portfolio | Tx | umbrella | Mehmood Khan, Tristan Edwards, John Amatruda, Jennifer Cermak, William Avery | Nir Barzilai, Lindsay Wu | info@lifebiosciences.com | Boston | no | 53 | 2017 | raised B | 75 | several portfolio companies | 2019-08-26 | |||||||||||||||||
76 | Life Length | yes | operating | telomere testing DTC & for drs & as contract research, also for cancer diagnostics | commercial | Dx | biomarkers / telomeres | telomeres | cancer | unreg test | Stephen Matlin, Pilar Najarro, Lissette Otero, Nuria De Pedro | Bill Andrews, Sandy Chang, Inderjeet Dokal, Mark Rosenberg, Jerry Shay, Takuji Shirasawa | info@lifelength.com | Madrid, Spain | no | 38 | 2010 | 2020-02-05 | 2020-02-05 | ||||||||||||||||
77 | LipidEv (Lipid Evolution Ltd.) | yes | operating | anti-inflammatory lipids (specialized proresolving mediators) that decline w/ age | pre-clinical | Tx | various agingDs & inflammatoryDs | Derek Clissold | info@lipidev.co.uk | Reading, UK | no | 1 | 2014 | related papers | 2019-08-02 | ||||||||||||||||||||
78 | Longeveron | yes | operating | allogeneic mesenchymal stem cells f/ bone marrow | ph.2 trials | Tx | stem cells | stem cells | cell loss | AF, AD, metabolicDs | 5 | cell therapy | pharma | Geoff Green, Joshua Hare, Anthony Oliva | Jeremy Walston, Laura Dugan, Elena Volpi, Hidenori Arai | form | Miami | no | 12 | 2014 | raised seed | 7 | 2019-08-23 | ||||||||||||
79 | Longevity Biotech | yes but see notes | operating | platform peptides long-lived w/ oral administration, 1st or neurodegeneration (via VIP receptors) & T2D | clinical trials | Tx | PD, neuroDs, T2D, cancer | 1 | peptides | pharma | Scott Shandler, Samuel Gellman, Uma sinha | William Degrado, Howard Gendelman, Soumitra Ghosh, Chris Rhodes, James Waschek | Info@LongevityBiotech.com | Philadelphia | no | 6 | 2010 | NMSS, Thiel/Breakout, MJF | 0.8 | LBT-3627, LBT-6030 | several | 2019-08-23 | Longevity in the name appears to refer to the stability of the peptides, not longevity of the patient. Nonetheless, the platform's early pipeline indications include a variety of age-related diseases, and mostly age-related diseases, even though aging/longevity doesn't seem to be a company mission or criterion, eg based on interview here: https://www.sciwri.club/archives/7375 | ||||||||||||
80 | Longevity Bridge | yes | operating | biomarkers of aging esp. NAD biomarkers, 1st through patient-funded study (also see notes) | pre-commercial | Dx | NAD+ | blood tests | unreg test | Maria Entraigues Abramson, Gary Abramson | Greg Fahy, Aubrey de Grey, Alexandra Stolzig, Michael Rae, Mike Kope | mail@longevitybridge.com | Los Angeles | no | 2 | 2017 | 2019-07-30 | LinkedIn company page self description suggests plan for DTC products/services for healthspan/lifespan. | |||||||||||||||||
81 | LyGenesis | yes | operating | regrow organs in lymph nodes f/ donor cells, 1st for liver diseases, later thymus, pancreas, & kidneys | pre-clinical ph.2 ready | Tx | stem cells, immune | stem cells | cell loss | liverDs | 1 | pharma | Michael Hufford, Paulo Fontes, Eric Lagasse | form | Pittsburgh | no | 5 | 2017 | raised A | Juvenescence, Longevity Vision Fund | 7 | Juvenescence | LYG-LIV0001 | 2 on liver, 2 on kidney | 2020-08-30 | ||||||||||
82 | Mesoblast | yes | operating | allogeneic mesenchymal stem cells for inflammatory conditions | ph.3 trials, JP EU approved | Tx | stem cells | stem cells | cell loss | GVHD, HF, chronic back pain, OA, diabetic nephropathy | 34 | cell therapy | pharma | Silviu Itescu, Fred Grossman, Roger Brown | info@mesoblast.com | Melbourne | yes | MESO | ?: Y&G disagree | 81 | 91 | 2004 | Revascor, Remestemcel-L, MPC-06-ID | many | some info | 2019-08-23 | A lot of focus on non-age-related conditions, but stem-cell tech clearly applicable to aging too with several aging-related indications. Claimed first allogeneic stem-cell therapy approved in Japan & first in Europe. | ||||||||
83 | Methuselah Health | yes | operating | protein post-translational modification analysis for drug discovery for proteostasis | pre-clinical | Tx | proteostasis | proteostasis | ex-cell aggregates | drugs | pharma | David Grainger, David Mosedale, Mary Donnelly | info@methuselah-health.com | Cambridge, UK | no | 2 | 2015 | Medicxi, Index Ventures | 2019-11-14 | 2019-11-14 | |||||||||||||||
84 | Minovia Therapeutics | yes | operating | autologous stem cells enriched w/ mitochondria to transfer to other cells, for mitochondria dysfunction | ph.2 trials | Tx | mitochondria / mito-transfusion, stem cells | mitochondria, stem cells? | mitochondria | NA mitoDs, AD, PD, AMD | 2 | cell therapy | pharma | Natalie Yivgi-Ohana, Noa Sher, Eyal Shoshani | info@minoviatx.com | Israel | no | 19 | 2011 | https://patents.justia.com/assignee/minovia-therapeutics-ltd | 2020-01-06 | Approval in Japan (see pipeline). Other company details at http://minovia.com/mitochondrial-augmentation-therapy/ & http://minovia.com/open-questions/ | |||||||||||||
85 | Mitochondrial Transfusion | yes | operating | extract stem cells, expand & extract youthful mitochondria, transfuse back to body | pre-clinical | Tx | mitochondria / mito-transfusion | mitochondria | mitochondria | AD, PD, CVD, sarcopenia | cell/organelle therapy | pharma | Tom B. | form | San Francisco | no | 1 | 2018 | 2020-04-29 | ||||||||||||||||
86 | Mitoconix Bio (not responding) | only brain | defunct? | drugs for mitochondria health for dementias, 1st by inhibiting pathological mito fission | pre-clinical | Tx | mitochondria | mitochondria | mitochondria | HD, PD, AD | peptides | pharma | was Gili Hart, Lior Weissma but LinkedIn reports both left summer 2019 | Daria Mochly-Rosen, Orian Shirihai | Israel | no | 4 | 2016 | raised A ('17) | FutuRx, Remiges, OrbiMed, Dementia Discovery Fund, Arix Bioscience, RMGP | 20 | 2020-01-06 | Failed?: Website not responding on 1/6/2020 executives report having ended employment there summer 2019 according to their LinkedIn profiles. | ||||||||||||
87 | Mitokinin | only brain | operating | develop neo-substrates that modify kinase activity for mitochondria & neuro diseases, 1st for PD | pre-clinical | Tx | mitochondria | mitochondria | mitochondria | PD, HD, other mito & neuroDs? | pharma | Kevan Shokat, Nicholas Hertz, Daniel de Louret | M. Flint Beal, X. William Yang, Ray Truant | San Francisco | no | 10 | 2017 | 5 | QB3 | https://patents.justia.com/assignee/mitokinin-llc | 2019-07-10 | ||||||||||||||
88 | Mount Tam -> Torcept | yes | rebooting? see notes | drug platform for mTOR modulating rapalogs with selective inhibition of mTORC1 | pre-clinical | Tx | metabolism / mTOR | nutri-sense | Lupus, MS, cancer, PD, HD | small molecules | pharma | Richard Marshak | Bryan Cox, Jim Stolzenbach | jim@mounttambiotech.com | Burlington, VT | yes | MNTM | not found | 2 | 2 | 2014 | TAM-01 | 2020-01-30 | Rebooting as Torcept Tx?: Mt Tam website not responding & seems delisted f/ markets. Richard Marshak's LI page says Torcept current. And SEC form says Mt Tam assets sold to Torcent. See: https://www.linkedin.com/in/richard-marshak-129a527/ & https://finance.yahoo.com/news/banner-announces-completion-merger-agreement-140000266.html & https://www.streetinsider.com/SEC+Filings/Form+8-K+Mount+TAM+Biotechnologie+For%3A+Nov+13/16156270.html | |||||||||||
89 | MyndYou | only brain | operating | cognition eval app w/ AI to passively track movement & conversation, platform for therapists | commercial | Dx | biomarkers | AD, other MCI | mobile app, telecom? | Ruth Poliakine Baruchi, Itay Baruchi, | form | Israel | no | 11 | 2016 | raised seed | Amplifyher, Female Founders Fund, Howard Morgan | Mizuho | 2019-07-22 | Company webpage indicates more palliative focus than other cognitive testing app companien (eg NeuroTrack, Altoida), but clearly the technology has the potential to be used as cognitive decline biomarker/diagnostic. Being deployed currently as more of a augmentative tool for therapists? | |||||||||||||||
90 | Napa Therapeutics | yes | operating | drug discovery pursuing novel targets related to NAD metabolism using drug discovery AI + NAD science | pre-clinical | Tx | NAD+ | small molecules | pharma | Qiuxia Wu | Eric Verdin (presumably not employee?) | San Francisco | no | 1 | 2019 | Juvenescence | 3 | Juvenescence, Insilico Medicine | 2020-02-20 | ||||||||||||||||
91 | Navitor Pharmaceuticals | yes | operating | drug discovery targeting mTORC1 modulation | ph.1 trials | Tx | metabolism / mTOR | nutri-sense | HD, MCI, depression muscle wasting | 1 | small molecules | pharma | George Vlasuk, Eddine Saiah, James ("Randy") Owen | David Sabatini, Michael Hall, Brian Hubbard, Brendan Manning, Mark Murcko | 3 emails | Boston | no | 24 | 2010 | raised C | Brace Pharma, J&J, Sanofi, SR One, Polaris, Longevity Fund | 78 | NV-5138 | several peer reviewed | 2019-07-31 | ||||||||||
92 | NemaLife Inc. | yes | operating | automating C.elegans HTS inc. healthpan/lifespan w/ microfluidics, computer vision, & data intelligence | commercial? | tool | lifespan screens | some specific worm disease models | tool as product, service | unreg tool | Siva Vanapalli, Mizanur Rahman | info@nemalifeinc.com | Lubbock, TX | no | 4 | 2018 | bioRxiv preprint | 2019-07-17 | the microfluidics approach distinguishes this from some other worm automation work, eg allowing automated removal of offspring to allow focus on the aging adult worms | ||||||||||||||||
93 | NeuroTrack | only brain | operating | eye-tracking cognitive (esp. memory) 5min test & multimodal lifestyle digital intervention program | commercial? | Dx, Tx | biomarkers | MCI | 3 | mobile app | reg Dx? | Elli Kaplan, Nick Bott, Jordan Glenn | John Harrison, Richard Isaacson, Dorene Rentz, Mike Poole | support@neurotrack.com | San Francisco | no | 43 | 2012 | raised C | Founders Fund, Khosla, Marc Benioff, Social Capital, Sozo Ventures | 50 | Imprint Memory Assessment | https://aging.jmir.org/2018/2/e12031/ | 2019-07-22 | |||||||||||
94 | Newomics | maybe | operating | microfluidics platform based on new emitter for improved LC-MS for multi-omics | commercial | Dx | biomarkers, senescence | senescence | senescence | AD, T2D | Daojing Wang, Doug Henry, Frank Slovenec, Pan Mao | Michael MacCoss, Jonathan Sweedler, Glenn Takayama | info@newomics.com | San Francisco | no | 15 | 2013 | raised seed | Berkeley Catalyst, Photon | 3.9 | QB3 | M3 Emitters, MEA Chip, Senescence Chip | several; notably for aging the senescence chip paper: https://www.ncbi.nlm.nih.gov/pubmed/?term=29336105 | 2019-12-25 | 2019-12-27 | Broader technology platform than aging. But the only specific diagnostics mentioned on about page were all aging related: diabetes, Alzheimer's, & senescent cells tests. Conclusion: include for now but re-evaluate later to see if non-aging is majority of the business. | |||||||||
95 | Nuchido | yes | operating | nutraceutical for NAD+ w/o NR, includes regulators of pathways that make/lower NAD+ | pre-commercial | Tx | NAD+ | nutraceuticals | supplement | Nichola Conlon | Tom Kirkwood | Newcastle, UK | no | 5 | 2017 | Deepbridge | Time Capsule | poster | 2019-08-09 | List of ingredients does not seem to be available yet. | |||||||||||||||
96 | NuSirt | yes | operating | supplements + existing drugs for low-cost discovery, targeting sirtuins (esp. Sirt1) for metabolic diseases | ph.2 trials | Tx | metabolism | nutri-sense | NAFLD, NASH, T2D, obesity, hypertension | 4 | small molecules, nutraceuticals | pharma, supplement | Joseph Cook, Michael Zemel, Barbara Cannon | Alan Cherrington, Zan Fleming, Orville Kolterman, Mary Rinella, Naga Chalasani | Info@NuSirt.com | Knoxville, TN | no | 3 | 2007 | raised C | 16 | NS-0100 | several papers | 2020-10-12 | 2020-10-12 | ||||||||||
97 | Oisin Bio (& OncoSenX) | yes | operating | targeted non-viral gene therapy based on DNA expression, for senescent cells & cancer (via spinout) | pre-clinical | Tx | senescence, DNA, targeted elimination | senescence, DNA | senescence, cancer | cancer (all solids), more TBD | non-viral gene therapy | pharma | Matt Scholz, Gary Hudson, John Lewis | form | Seattle | no | 12 | 2014 | closed seed | Methuselah, Kizoo | 3 | Entos Pharmaceuticals | 2019-07-31 | Spun out OncoSenX for cancer (not on this list since devoted only to cancer, but for the purposes of this list the 2 companies are best considered as one). | |||||||||||
98 | OneSkin Technologies | yes | operating | screening platform using 3D human skin culture & skin age clock, 1st therapy a topical senolytic peptide | pre-clinical | Tx | senescence | senescence | senescence | peptide for topical use | reg cosmetic | Carolina Oliveira, Andres Ochoa, Alessandra Zonari, Mariana Boroni | information@oneskintech.com | San Francisco | no | 10 | 2016 | raised seed | SOSV/IndieBio | 2.2 | QB3 | OS-1, OS-2 | 2019-08-02 | ||||||||||||
99 | OpenCures (was OpenOme) | yes | operating | DTC metabolomics & proteomics tests; plasmalogen supplement | commercial (limited early access) | Dx | biomarkers | blood test | unreg test | Kevin Perrott, Mark Hamalainen, Chandra Duggirala | Aubrey de Grey, Nathan Price, Jim O'Neill, Lei Ding, Christine Peterson, Michael MacCoss | contact@opencures.org | San Francisco | no | 1 | 2018 | 2020-04-28 | ||||||||||||||||||
100 | Osiris Green | yes | defunct? | DTC methylation clock, but probably gone now | commercial | Dx | biomarkers / methylome clock | epigenetic | blood test or urine test | unreg test | Neil Copes | form | Tampa, FL? | no | 1 | 2016 | 2020-01-06 | Probably out of business: As of July 2019 website wasn't accepting orders. As of Jan 2020, website no longer exists. Founder Copes' LinkedIn page doesn't suggest a newer job yet though. |